{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:56:42Z","timestamp":1761742602189},"reference-count":20,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T00:00:00Z","timestamp":1363651200000},"content-version":"vor","delay-in-days":2787,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:p>ABT\u2010578, a sirolimus analog, is being developed for administration from drug\u2010eluting stents to prevent postimplantation neointimal hyperplasia. The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of ABT\u2010578. Healthy subjects randomly received placebo or ABT\u2010578 (200, 400, or 800 \u03bcg) as daily intravenous infusions for 14 days. ABT\u2010578 blood pharmacokinetics and urine excretion on days 1 and 14 were determined. The effect of ABT\u2010578 on mitogen\u2010stimulated lymphocyte proliferation was assessed. ABT\u2010578 pharmacokinetics was described by a 3\u2010compartment open model. The mean CL, V<jats:sub>ss<\/jats:sub>, and t<jats:sub>1\/2<\/jats:sub> ranges were 4.0 to 4.6 L\/h, 92.5 to 118.0 L, and 24.7 to 31.0 hours, respectively. ABT\u2010578 pharmacokinetics was dose and time invariant. Approximately 0.1% of ABT\u2010578 was excreted in the urine. ABT\u2010578 was well tolerated, and no systemic changes were observed in the mitogen\u2010stimulated lymphocyte proliferation. ABT\u2010578 was shown to be safe over a wide range of systemic exposures.<\/jats:p>","DOI":"10.1177\/0091270005278807","type":"journal-article","created":{"date-parts":[[2005,7,18]],"date-time":"2005-07-18T21:03:28Z","timestamp":1121720608000},"page":"910-918","source":"Crossref","is-referenced-by-count":12,"title":["A Phase I Multiple\u2010Dose Escalation Study Characterizing Pharmacokinetics and Safety of ABT\u2010578 in Healthy Subjects"],"prefix":"10.1002","volume":"45","author":[{"given":"Chetan S.","family":"Karyekar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajendra S.","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Freeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timi","family":"Edeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzi","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid M.","family":"Awni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Locke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis B.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Granneman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"O'Dea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,19]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1522-1865(00)00081-0"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00001958"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408253310802"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408253310801"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392304"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000038984.30279.89"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035071"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(03)00211-2"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(98)00045-9"},{"key":"e_1_2_5_11_2","volume-title":"Comparison of Potencies of ABT\u2010578 and Rapamycin in Inhibiting Human Coronary Artery Smooth Muscle Cell Proliferation","author":"Chen Y","year":"2002"},{"key":"e_1_2_5_12_2","volume-title":"Comparative Potency of ABT\u2010578, Sirolimus, Everolimus, Tacrolimus, Paclitaxel, and Dexamethasone in Inhibiting Human Coronary Artery Smooth Muscle Cell Proliferation In Vitro","author":"Chen Y","year":"2004"},{"key":"e_1_2_5_13_2","unstructured":"BurkeSE TonerJL CromackKR et al.ABT\u2010578 paclitaxel and rapamycin\u2010eluting stents show similar efficacy in a porcine model of coronary restenosis. Poster presented at: Annual Meeting of Cardiovascular Revascularization Therapies (CRT);March 2005; Washington DC."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.02.014"},{"key":"e_1_2_5_15_2","volume-title":"Harrison's Principles of Internal Medicine","author":"Braunwald E","year":"2004"},{"key":"e_1_2_5_16_2","volume-title":"Toxicological Evaluation of Certain Food Additives with a Review of General Principles and of Specifications: 17th Report of the Joint\/WHO Expert Committee on Food Additives","author":"World Health Organization","year":"1974"},{"key":"e_1_2_5_17_2","first-page":"M1096","article-title":"Safety and pharmacokinetics of single, escalating, intravenous doses of ABT\u2010578 in healthy male subjects [abstract]","volume":"6","author":"Palaparthy R","year":"2004","journal-title":"AAPS J"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199311000-00029"},{"key":"e_1_2_5_19_2","volume-title":"In Vitro Distribution of [3H]A\u2010179578 in Human Whole Blood","author":"McCracken NW","year":"2004"},{"key":"e_1_2_5_20_2","volume-title":"The Metabolism, Excretion and Tissue Distribution of [14C] Abbott\u2010179578 in Rabbits","author":"Murray B","year":"2002"},{"key":"e_1_2_5_21_2","volume-title":"Wyeth Laboratories. Sirolimus (Rapamune) [prescribing information]","year":"2001"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270005278807","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270005278807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:21:11Z","timestamp":1697156471000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270005278807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1177\/0091270005278807"],"URL":"https:\/\/doi.org\/10.1177\/0091270005278807","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}